A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma (NCT05621668)

🧪 Interventions in This Study

• Cyclophosphamide (DRUG)
• attIL2-T cells (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

• M D Anderson Cancer Center — Houston, Texas

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Soft Tissue Sarcoma

• Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma — St Louis, Missouri
• Dose Reduction of Postoperative Radiation for Soft Tissue Sarcoma of the Arms and Legs — Basking Ridge, New Jersey
• Hypofractionated Radiotherapy for Soft Tissue Sarcomas — Madison, Wisconsin
• TVEC and Preop Radiation for Sarcoma (8 ml Dose) — Iowa City, Iowa
• Study to Assess TOPO2A as a Biomarker for Sensitivity to Doxorubicin/Doxil in Soft Tissue Sarcoma — Philadelphia, Pennsylvania

Explore by condition: All Soft Tissue Sarcoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.